ClinicalTrials.gg
CompletedNCT06346340Updated Jul 6, 2026Results posted

A Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

A Phase 4 interventional study of Miebo in Dry Eye, sponsored by Bausch & Lomb Incorporated. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
97
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes — 1 open to participants now, 2 under way, none of them phase 3. perfluorohexyloctane · Dry Eye Syndromes.

Enrollment
11th of 13
97 · median 216
Started
2024
with 2 others
Phase 4
7 of 13
1 open now
Registered
7th of 13
by date
Lead sponsor
9 of 13
Bausch & Lomb Incorporated

Among the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, this one is the 11th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 4, and was the 7th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

1 of the 13 studies testing perfluorohexyloctane in Dry Eye Syndromes is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About perfluorohexyloctane

perfluorohexyloctane: first FDA approval 2023 (MIEBO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing perfluorohexyloctane in Dry Eye Syndromes, or all of them as a file.
02

Study summary

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/ Keratometry and Postoperative Refractive Accuracy

Read the detailed description

The primary objective is to determine the effect of preoperative Miebo treatment on the accuracy of preoperative biometry/keratometry and predicted refraction in subjects with dry eye disease (DED) who are already scheduled for cataract surgery.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the time of consent
  2. Able to provide written voluntary
  3. The same eye must satisfy the below inclusion criteria (a-e):

    1. At least 1 eye with a visually significant cataract that has been scheduled for cataract surgery (eligible eye can be a subject's second eye to undergo cataract surgery as long as all eligibility criteria are met in that eye)
    2. Candidate for routine, uncomplicated cataract surgery (phacoemulsification with posterior chamber intraocular lens [IOL] implantation, not combined with any other surgery)
    3. In the Investigator's opinion, subject has potential postoperative pinhole Snellen visual acuity of at least 20/200 in both eyes
    4. Tear film break-up time ≤10 sec at Visit 1
    5. Total CFS score ≥2 and ≤11 (ie, sum of inferior, superior, central, nasal, and temporal), using the National Eye Institute scale at Visit 1
  4. Ocular Surface Disease Index (OSDI) ≥23 at Visit 1
  5. Able and willing to follow instructions, including participation in all trial assessments and visits.

Exclusion criteria

Exclusion Criteria:

  1. Have any ocular surface slit-lamp findings in the study eye and/or, in the opinion of the Investigator, have any findings that could interfere with trial parameters, including:

    1. History of eye trauma
    2. History of Stevens-Johnson syndrome
    3. Active blepharitis or lid margin inflammation
    4. DED secondary to scarring, irradiation, alkali burns, cicatricial pemphigoid, or destruction of conjunctival goblet cells (as with vitamin A deficiency)
    5. Abnormal lid anatomy causing incomplete eyelid closure
    6. Abnormal cornea shape (keratoconus)
    7. Corneal epithelial defect or significant confluent staining or filaments
    8. History of herpetic keratitis
    9. Ocular or periocular rosacea
  2. Pterygium in either eye
  3. Use of any of the following ocular therapies in the study eye within 30 days prior to Visit 1: Vuity®, Qlosi™, topical ocular treatments, prescription dry eye therapy including varenicline nasal spray, or topical anti-glaucoma medication
  4. Had a LipiFlow® procedure, intense pulse light procedure, or any kind of other procedure affecting meibomian glands in the study eye within 3 months prior to Visit 1
  5. Had received or removed a permanent punctum plug in the study eye within 1 month (3 months for dissolvable punctum plugs) prior to Visit 1
  6. Use of any eye drops (prescription or over-the-counter, such as artificial tears or Lumify®) and/orTrueTear™ device (intranasal tear neurostimulator) in the study eye within 24 hours prior to Visit 1
  7. Have active ocular allergies or ocular allergies that are expected to be active during the trial period
  8. Have worn contact lenses within 1 month prior to Visit 1 or planned wear during the study
  9. Have undergone intraocular surgery or ocular laser surgery in the study eye within 3 months prior to Visit 1; have undergone refractive surgery in the study eye within 2 years prior to Visit 1
  10. Have active ocular or systemic infection (bacterial, viral, or fungal), including fever
  11. Female subjects who are pregnant, nursing, or planning a pregnancy
  12. Female subjects of who are not using an acceptable means of ; acceptable methods of contraception include hormonal (oral, implantable, injectable, or transdermal) contraception; mechanical (spermicide in conjunction with a barrier such as a diaphragm or condom) contraception; intrauterine device; or surgical sterilization of partner. For non-sexually active female subjects, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the trial, she must agree to use adequate birth control as defined above for the remainder of the trial.
  13. Have an uncontrolled systemic disease that, in the opinion of the Investigator, will interfere with the trial
  14. Have a known allergy and/or sensitivity to the drug
  15. Use of any oral medications known to cause ocular drying (eg, antihistamines, antidepressants, etc.) on a non-stable regimen within 1 month prior to Visit 1 or is expected to be unstable during the trial
  16. Have taken isotretinoin (eg, Accutane, Myorisan, Claravis, Amnesteem) within 6 months prior to Visit 1
  17. Are currently enrolled in an investigational drug or device study or had used an investigational drug or device within 60 days prior to Visit 1.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Experimental
    Miebo treatment

    Drug: Miebo

Interventions

  • DrugMiebo

    Miebo applied in both eyes 4 times per day for approximately 30 days before cataract surgery. Following the completion of the standard follow up, approximately 30 days after cataract surgery, subjects will begin a second regimen of Miebo , 4 times per day in both eyes, for approximately 30 days.

06

What researchers measure

Primary outcomes

  1. Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.

    Mean difference between absolute deviations from predicted refractive error in the study eye at Visit 3 (Second Eye/Unilateral Postop Day 30 ± 7 days).

    Time frame: Assessed at Postop Day 30 ± 7 days

07

Results

Posted Jul 6, 2026

Participant flow

Participant flow — Overall Study
MilestoneMiebo Treatment
Started97
Completed85
Not completed12

Outcome measures

PrimaryMean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.

Mean difference between absolute deviations from predicted refractive error in the study eye at Visit 3 (Second Eye/Unilateral Postop Day 30 ± 7 days).

Time frame:
Assessed at Postop Day 30 ± 7 days
Reported as:
Mean · Diopters
Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.
DioptersMiebo Treatment
Mean Difference Between Absolute Deviations From Predicted Refractive Error in the Study Eye.-0.027 ± 0.167

Adverse events

Collected over Assessed for 118 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Miebo Treatment0/97 (0%)2/97 (2.1%)5/97 (5.2%)
Most frequent serious events
Most frequent serious events
EventMiebo Treatment
IridoceleEye disorders1/97
PneumoniaInfections and infestations1/97
Most frequent other events
Most frequent other events
EventMiebo Treatment
Intraocular pressure increasedEye disorders5/97

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Miebo Treatment
<=18 years0
Between 18 and 65 years25
>=65 years72
Sex: Female, Male
Sex: Female, Male(Participants)Miebo Treatment
Female73
Male24
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Miebo Treatment
American Indian or Alaska Native3
Asian6
Native Hawaiian or Other Pacific Islander1
Black or African American7
White78
More than one race2
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Miebo Treatment
United States97
08

Study locations

12 sites
  • Site 105
    Laguna Hills, California 92655, United States
  • Site 102
    Petaluma, California 92954, United States
  • Site 109
    Sacramento, California 94206, United States
  • Site 111
    Grand Junction, Colorado 81501, United States
  • Site 103
    Largo, Florida 33770, United States
  • Site 106
    Oak Lawn, Illinois 60453, United States
  • Site 108
    Alexandria, Minnesota 56308, United States
  • Site 104
    St Louis, Missouri 63131, United States
  • Site 101
    Somersworth, New Hampshire 03878, United States
  • Site 107
    Sioux Falls, South Dakota 57108, United States
  • Site 110
    San Antonio, Texas 78229, United States
  • Site 112
    San Antonio, Texas 78229, United States
09

References and documents

Publications

  • Hovanesian JA, Liang E, Desai NR, Berdy GJ, Karpuk K, Schweitzer J, Alexander A, Vittitow JL, Berdahl J, Bacharach J. Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Undergoing Cataract Surgery: A Prospective Multicenter Study. Ophthalmol Ther. 2026 Feb;15(2):817-829. doi: 10.1007/s40123-025-01302-z. Epub 2026 Jan 26. PubMed 41588216 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Feb 2025, 9 months.

Results were first posted in Jul 2026, 1 year 4 months after primary completion.

Of 28 industry-sponsored phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 15. This study's 9 months is above that.

Counting every sponsor, half of 112 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 4, 2024
StartActual
Apr 30, 2024
Primary completionActual
Feb 24, 2025
CompletionActual
Feb 24, 2025
Results first posted
Jul 6, 2026
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06346340
Responsible party
Sponsor
First posted
Apr 4, 2024
Start date
Apr 30, 2024
Primary completion
Feb 24, 2025
Completion
Feb 24, 2025
Results posted
Jul 6, 2026
Last update
Jul 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perfluorohexyloctane

Start the discussion